FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer

, , , ,

On Nov. 15, 2026, Roche announced that the U.S. Food and Drug Administration (FDA) has approved Wilserdly™ (giredestrant) in combination with everolimus for the treatment of adults with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorised test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.

The approval of Wilserdly addresses an important unmet need for patients developing resistance. Up to 40% of patients with hormone receptor (HR)-positive metastatic breast cancer develop ESR1 mutations that drive resistance and disease progression. Wilserdly plus everolimus addresses this by targeting two different signalling pathways while helping to minimise the impact of treatment on people’s lives as an oral regimen without the need for injections.

The FDA approval is supported by positive primary endpoint data from the phase III evERA Breast Cancer study published in

Globally, the burden of breast cancer continues to grow, with 2.3 million women diagnosed and 670,000 dying from the disease every year. Breast cancer remains the number one cause of cancer-related deaths amongst women, and the second most common cancer type. HR-positive, human epidermal growth factor receptor 2-negative breast cancer accounts for approximately 70% of breast cancer cases and more than 90% are diagnosed in the early-stage. A defining feature of HR-positive breast cancer is that its tumour cells have receptors that attach to hormones like oestrogen, which can contribute to tumour growth.

Despite treatment advances, HR-positive breast cancer remains particularly challenging to treat due to its biological complexity. Patients often face the risk of disease progression, treatment side effects and resistance to endocrine therapy. There is an urgent need for more effective treatments that can delay clinical progression and reduce the burden of treatment on people’s lives.. In adult patients with ESR1-mutated, ER-positive, HER2-negative locally advanced or metastatic breast cancer progressing after prior cyclin-dependent kinase (CDK)4/6 inhibitor therapy, the all-oral combination of Wilserdly plus everolimus significantly prolonged progression-free survival, achieving a 62% reduction in the risk of disease progression or death compared to standard endocrine therapy plus everolimus (stratified hazard ratio=0.38; 95% confidence interval: 0.27–0.54; p<0.0001).

Tags:


Source: Roche
Credit:

Advertise in our E-history sent to 5,000 plus company decision makers twice per month for only $300 per month. Reserve your space now! E-mail: info@LifeScienceHistory.com.